Univa Health Launches NHS-Supported Clinical Study to Transform Eating Disorder Care with Smart Device Biomarker Technology
London, UK 8th December 2024 – Univa Health, a pioneering health technology company has officially commenced recruitment last month for a landmark clinical study, The Use of Smart Devices in Capturing Biomarkers in Eating Disorders. This multi-site study conducted in collaboration with nine of the UK’s National Health Service hospital trusts, is set to revolutionise how eating disorders are monitored and managed, leveraging the power of smart devices to provide non-invasive, real-time data collection.
This first-of-its-kind initiative aims to create digital biomarkers—quantifiable measurements captured through smart devices—to provide clinicians with continuous high-fidelity insights into a patient's physical and mental health. By collecting these biomarkers remotely, the study seeks to empower healthcare providers to offer more personalised, proactive care while reducing the strain on both patients and clinical resources.
"At Univa, we believe in harnessing technology to bridge the gap between possibility and practicality in healthcare," said Rich Andrews, CEO and Co-Founder of Univa Health. "By leveraging smart devices to create real-time, data-driven insights, we’re breaking down barriers to personalised care. Our goal is to give patients greater agency in their recovery journey while equipping clinicians with the tools they need to make timely, informed decisions."
A New Era of Eating Disorder Monitoring
Traditional methods for monitoring eating disorders are often invasive, resource-intensive, and distressing for patients. Univa Health's innovative approach harnesses smartphone technology and wearable devices to collect and analyze a broad range of physiological and psychological biomarkers. These include physiological biomarkers such as weight changes, blood pressure, blood oxygenation, and hydration status, and psychological biomarkers such as mood, anxiety, and emotional distress.
The study will also explore emerging biomarker technologies, including voice pattern analysis and facial morphology tracking, to detect subtle changes that could signal shifts in a patient’s health trajectory. This groundbreaking approach could enable earlier intervention strategies and significantly improve patient outcomes.
"This study is about much more than a new monitoring tool," said Professor Dan Joyce, Chief Investigator for the study, a psychiatrist and data scientist at the University of Liverpool. "It’s about building a foundational platform that will change how we understand, monitor, and treat eating disorders. Our goal is to reduce the burden on patients and provide clinicians with more timely, accurate and data-driven insights to improve care."
Collaborative Approach for a National Impact
Univa’s clinical study has been designed with diversity, inclusion, and scalability in mind. Univa Health aims to collect data from a broad population spanning children, adolescents, and adults with varying severities of eating disorders. To achieve this, the study is being conducted across nine NHS mental health trusts in England, including locations in London, the Midlands, and the North of England.
Participants will be enrolled for up to 16 weeks, enabling the study to build a comprehensive, longitudinal dataset that captures the progression and treatment response of patients over time. The study's design ensures that the findings will be applicable across diverse demographics, clinical settings, and stages of recovery.
"By collecting rich, near real-time data from such a diverse group of patients, we’re not just developing a technology—we’re building a clinical evidence base that could transform the standard of care for eating disorders," added Professor Joyce.
About Univa Health
Founded in 2024, Univa Health is a UK-based health technology company transforming eating disorder care through a clinically validated, evidence-based platform. By integrating real-time monitoring of physiological and psychological biomarkers with interactive therapeutic modules, Univa empowers healthcare providers to deliver proactive, personalised, and adaptive care. This approach aims to enable earlier intervention, more effective treatment strategies, and sustained recovery, improving long-term outcomes for patients and supporting families with accessible, compassionate care.
Univa Health has successfully raised £1 million in a pre-seed investment round led by Germany-based YZR Capital, and backed by Austria-based Calm/Storm Ventures, two of Europe's most active healthtech investors. The funding will support the development and commercialisation of Univa's personalised digital care platform, designed to transform how healthcare systems manage and treat eating disorders while improving the lives of those affected and their loved ones. The investment will also fund Univa's first clinical study, beginning in October, in collaboration with the UK's NHS as well as help build the tech, product, and clinical teams needed for the platform's launch in early 2025.
Co-founded by healthcare entrepreneurs Rich Andrews and Jose Santos, Univa is addressing the critical challenges in eating disorder care. Over the past five years, hospital admissions for eating disorders have surged by 84% in the UK and 121% in the US, highlighting the urgent need to tackle the devastating impact of inaccessible and ineffective care.
The heterogeneity of eating disorders further complicates treatment, as many healthcare services rely on one-size-fits-all approaches. This lack of personalisation, combined with a shortage of skilled clinicians, results in half of those with eating disorders not responding to treatment. In 2023 alone, nearly 30,000 people in the UK were admitted to hospital for eating disorders, with stays typically lasting three to four months. Despite the need for early intervention, the NHS is only able to provide care for 10% of adults with eating disorders. Nearly half of urgent cases for children waited more than 12 weeks for treatment. This backlog forces systems to prioritise only the most severe cases, leaving many without timely, tailored care that reflects the complexity of their conditions.
Rich Andrews, co-founder and CEO of Univa, commented:
“The widening gap between the need for care and available resources, along with the lack of personalised treatment options, urgently requires a radical rethink of how eating disorder care is provided. Our goal is to revolutionise care pathways, providing tools that empower clinicians and deliver meaningful results. We aim to keep people out of hospital and enable better long-term recovery while saving costs for the healthcare system. Univa's platform will augment the overwhelmed clinical workforce by providing evidence-based tools to reach more patients and families, enabling earlier intervention, improved monitoring, and faster recovery.”
Univa addresses these challenges by offering a range of digital tools to enhance the management, monitoring, and treatment of eating disorders. These tools include tailored therapeutic programs, AI-driven health monitoring features, and real stories from individuals who have lived through eating disorders, delivered through interconnected apps for both patients and their carers. By involving families in the care process, Univa's platform maximises treatment results and eases the burden on clinical teams.
Clinicians can use the platform's professional portal to create tailored treatment plans and monitor patient well-being in real time. This approach allows for more individualised care and enables clinical teams to allocate resources more efficiently, ensuring that those most in need receive timely support while patients further along in their recovery continue to receive the necessary guidance and care.
Rich Andrews, co-founder and CEO, brings relevant experience from founding Healios and leading the company for over a decade to become the largest mental health and neurodevelopmental digital clinic in the UK for children and young people. He then expanded Healios into the US under the brand name Meliora Health before stepping away and starting Univa.
Jose Santos, co-founder and CTO, also brings relevant experience from over a decade in the digital health field at several companies. Most recently, after his wife was diagnosed with multiple sclerosis (MS) he co-founded Indivi in 2017 to build dreaMSMD, the world’s first CE-marked digital biomarker platform to help patients with MS and their neurologists to better track and manage their condition.
Reinhard Meier MD MBA, Founding Partner at YZR Capital commented: "We at YZR believe in supporting transformative innovations that address urgent healthcare challenges. Univa's approach to personalising eating disorder care represents a significant leap forward, offering a scalable solution to an issue affecting millions worldwide. We were particularly impressed by Rich's experience as a serial entrepreneur, as well as the team's connections to the NHS system, which strengthens Univa's potential for real-world impact across the UK. We are excited to back such an experienced and passionate team, and we look forward to seeing Univa's platform make a lasting impact on both patients and the healthcare system."
Johannes Blaschke, Principal at Calm/Storm Ventures added: “At Calm/Storm, we seek out founders tackling systemic healthcare challenges with innovative, cutting-edge technology, and Univa Health exemplifies this with their transformative approach to eating disorder care. By leveraging an advanced, personalised platform that integrates both patient and caregiver tools, Univa is addressing one of the most complex and underserved areas in healthcare. With Rich and Jose’s deep experience in digital health and their strong clinical partnerships, we are confident that their AI-driven platform will significantly improve outcomes for those affected by eating disorders while also easing the burden on healthcare systems globally. This is exactly the kind of bold, purpose-driven healthtech innovation we are proud to support.”
About Univa Health
Founded in 2024, UK-based Univa is on a mission to address the profound impact of eating disorders on individuals and their families. The company’s vision is to create a platform grounded in clinical evidence that helps healthcare systems overcome access challenges and provide compassionate, high-quality and personalised care in a cost-efficient way. Univa’s digital tools for healthcare teams, patients, and families are integrated into clinical workflows to transform how eating disorders are addressed, monitored, and treated, aiming for better long-term results and recovery for those affected.
About YZR
YZR Capital is a €100m health tech fund investing in disruptive early-stage companies that are driving meaningful tech advancements in healthcare improving patient outcomes and enhancing the efficiency of healthcare systems. The unique team setup includes health tech founders, professional investors, physicians and former C-level healthcare executives. YZR Capital backs outstanding entrepreneurs and their ideas that are reshaping the future of healthcare through technology with capital and healthcare-specific expertise to create global champions.
About Calm/Storm Ventures
Calm/Storm Ventures, the most active early-stage healthtech fund in Europe, has solidified its position as a leading force in the industry with over 80 investments in the past three years. With a relentless focus on innovative healthcare startups, Calm/Storm continues to shape the future of the healthtech landscape, nurturing groundbreaking ideas that have the potential to revolutionize healthcare. They invest in purpose-driven founders who are transforming life, health, and wellbeing for the better.
Contact for press enquiries:
Rich Andrews
rich@univa.health